- Home
- RMM vs TVRD Comparison
RMM vs TVRD Comparison
Compare RMM & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMM
- TVRD
- Stock Information
- Founded
- RMM 2019
- TVRD 2017
- Country
- RMM United States
- TVRD United States
- Employees
- RMM N/A
- TVRD N/A
- Industry
- RMM Trusts Except Educational Religious and Charitable
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- RMM Finance
- TVRD Health Care
- Exchange
- RMM Nasdaq
- TVRD Nasdaq
- Market Cap
- RMM 271.2M
- TVRD 246.5M
- IPO Year
- RMM N/A
- TVRD N/A
- Fundamental
- Price
- RMM $13.38
- TVRD $25.77
- Analyst Decision
- RMM
- TVRD Strong Buy
- Analyst Count
- RMM 0
- TVRD 3
- Target Price
- RMM N/A
- TVRD $60.67
- AVG Volume (30 Days)
- RMM 66.5K
- TVRD 76.5K
- Earning Date
- RMM 01-01-0001
- TVRD 05-13-2025
- Dividend Yield
- RMM 7.33%
- TVRD N/A
- EPS Growth
- RMM N/A
- TVRD N/A
- EPS
- RMM 0.96
- TVRD N/A
- Revenue
- RMM N/A
- TVRD N/A
- Revenue This Year
- RMM N/A
- TVRD N/A
- Revenue Next Year
- RMM N/A
- TVRD N/A
- P/E Ratio
- RMM $15.55
- TVRD N/A
- Revenue Growth
- RMM N/A
- TVRD N/A
- 52 Week Low
- RMM $12.32
- TVRD $8.13
- 52 Week High
- RMM $16.10
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- RMM 36.11
- TVRD N/A
- Support Level
- RMM $13.41
- TVRD N/A
- Resistance Level
- RMM $13.57
- TVRD N/A
- Average True Range (ATR)
- RMM 0.10
- TVRD 0.00
- MACD
- RMM -0.02
- TVRD 0.00
- Stochastic Oscillator
- RMM 2.86
- TVRD 0.00
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.